Skip to main content
Jiangsu Recbio Technology Co., Ltd. logo

Jiangsu Recbio Technology Co., Ltd. — Investor Relations & Filings

Ticker · 2179 LEI · 254900UBG3389KI4UR87 HKEX Manufacturing
Open in API
Filings indexed 242 across all filing types
Latest filing 2026-01-30 Regulatory Filings
Country CN China
Listing HKEX 2179

About Jiangsu Recbio Technology Co., Ltd.

http://www.recbio.cn

Jiangsu Recbio Technology Co., Ltd. is an innovative vaccine company focused on the research, development, and commercialization of subunit vaccines. The company leverages proprietary technology platforms, including novel adjuvant systems, protein engineering, and immune evaluation. Recbio is one of the few global entities capable of independently developing and manufacturing a full spectrum of novel vaccine adjuvants. The portfolio comprises over ten differentiated innovative vaccines targeting major diseases such as cervical cancer (HPV), herpes zoster (shingles), and respiratory syncytial virus (RSV). Key pipeline assets in China Phase III clinical studies include the recombinant 9-valent HPV vaccine (REC603) and the novel adjuvant recombinant herpes zoster vaccine (REC610). Manufacturing facilities are designed to comply with WHO PQ and EU GMP standards, supporting clinical supply and future commercialization, notably including a high-capacity facility for the 9-valent HPV vaccine.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION ANNOUNCEMENT ISSUANCE OF FILING NOTICE BY THE CSRC FOR THE H SHARE FULL CIRCULATION PLAN OF THE COMPANY
Regulatory Filings Classification · 1% confidence The document is an 'Inside Information Announcement' from Jiangsu Recbio Technology Co., Ltd. regarding the receipt of a filing notice from the CSRC for an 'H Share Full Circulation' plan. This involves the conversion of unlisted shares into H shares, which is a capital structure change. While it involves regulatory filings, it specifically details the conversion of shares and the impact on the company's capital structure, fitting the 'Share Issue/Capital Change' (SHA) category as it pertains to the transformation and listing of existing unlisted shares into tradable H shares.
2026-01-30 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
Share Issue/Capital Change Classification · 1% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory filing used by issuers to report monthly movements in their securities, including share capital, issued shares, and treasury shares. Since it details specific changes in share capital (a new share issuance) and is a mandatory regulatory disclosure under the Exchange Listing Rules, it falls under the 'Share Issue/Capital Change' category.
2026-01-05 English
VOLUNTARY ANNOUNCEMENT ACCEPTANCE OF THE NEW DRUG APPLICATION FOR THE COMPANY'S NOVEL ADJUVANTED RECOMBINANT SHINGLES VACCINE REC610 BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement issued by Jiangsu Recbio Technology Co., Ltd. regarding the acceptance of a New Drug Application (NDA) for their shingles vaccine (REC610) by the National Medical Products Administration. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a regulatory announcement regarding business operations and product development that does not fall into the other specialized categories, it is classified as a general regulatory filing.
2025-12-29 English
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Board/Management Information Classification · 1% confidence The document is titled 'LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS' and provides a detailed breakdown of the board members, their roles (Chairman, Executive, Non-executive, Independent), and their committee memberships. This type of disclosure is a standard corporate governance filing required by stock exchanges to inform shareholders about the composition and structure of the board. It does not announce a change in management (MANG), but rather lists the current state of the board, which falls under Governance Information.
2025-12-23 English
CHANGE OF THE CHAIRMAN OF THE BOARD OF DIRECTORS AND ADJUSTMENT TO THE COMPOSITION OF THE NOMINATION COMMITTEE
Board/Management Information Classification · 1% confidence The document is an official announcement from Jiangsu Recbio Technology Co., Ltd. regarding the resignation of the Chairman of the Board and the subsequent appointment of a new Chairman, as well as adjustments to the composition of the Nomination Committee. This falls directly under the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-12-23 English
RULES OF PROCEDURE FOR THE BOARD OF DIRECTORS
Governance Information Classification · 1% confidence The document is titled 'Rules of Procedure for the Board of Directors' for Jiangsu Recbio Technology Co., Ltd. It outlines the internal governance structure, meeting protocols, and decision-making processes for the Board. This type of document falls under corporate governance policies and internal regulations, which are categorized as Governance Information (CGR) in the provided schema.
2025-12-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.